The estimated Net Worth of John B Moriarty is at least $5.57 Million dollars as of 6 February 2018. Mr Moriarty owns over 3,363 units of Olema Pharmaceuticals stock worth over $919,787 and over the last 12 years he sold OLMA stock worth over $4,215,829. In addition, he makes $434,324 as Exec. VP und Chief Legal Officer & Corp. Sec. at Olema Pharmaceuticals.
Mr has made over 23 trades of the Olema Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 3,363 units of OLMA stock worth $389,099 on 6 February 2018.
The largest trade he's ever made was exercising 20,000 units of Olema Pharmaceuticals stock on 5 August 2015 worth over $1,853,000. On average, Mr trades about 2,208 units every 50 days since 2012. As of 6 February 2018 he still owns at least 74,537 units of Olema Pharmaceuticals stock.
You can see the complete history of Mr Moriarty stock trades at the bottom of the page.
John B. Moriarty Jr. is the Exec. VP, Chief Legal Officer & Corp. Sec. at Olema Pharmaceuticals.
As the Exec. VP und Chief Legal Officer & Corp. Sec. of Olema Pharmaceuticals, the total compensation of Mr Jr at Olema Pharmaceuticals is $434,324. There are 3 executives at Olema Pharmaceuticals getting paid more, with Dr. Sean P. Bohen M.D., Ph.D. having the highest compensation of $999,300.
Mr Jr is 53, he's been the Exec. VP und Chief Legal Officer & Corp. Sec. of Olema Pharmaceuticals since . There are 4 older and 4 younger executives at Olema Pharmaceuticals. The oldest executive at Olema Pharmaceuticals, Inc. is Dr. Peter J. Kushner Ph.D., 82, who is the Chief Scientific Officer.
John's mailing address filed with the SEC is C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham und Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals executives and other stock owners filed with the SEC include: